JCM
BPMC

JS Capital Management’s Blueprint Medicines BPMC Stock Holding History

JS Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,000
Closed -$2M – 77
2019
Q1 		$2M Buy
+25,000
New +$1.85M 0.42% 22

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JS Capital Management's BPMC Position: Q2 2019 in Review

JS Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 25,000 shares — an estimated $2M sold.

JS Capital Management first reported a position in BPMC in Q1 2019 and held it in 1 quarter. The position peaked at $2M in Q1 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

  • JS Capital Management reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
  • JS Capital Management sold 25,000 Blueprint Medicines shares in Q2 2019, an estimated $2M.
  • JS Capital Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 1 quarter.
  • JS Capital Management's Blueprint Medicines position peaked at $2M in Q1 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on JS Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.